Categories Analysis, Finance

Up next in Chinese stock earnings – Qudian

Following the earnings announcements of US-listed Chinese firms including JD.com (NASDAQ: JD), Tencent Music (NYSE: TME), Gogo (NASDAQ: GOGO) and Luckin Coffee (NASDAQ: LK), fintech firm Qudian (NYSE: QD) is set to post quarterly results on Friday, August 16, before the regular trading hours.

Notably, Qudian is one of the few US-listed Chinese firms that have performed relatively well in the backdrop of US-China trade spat as well as a slowing economy back home. The stock has doubled since the beginning of this year, but is still considered underpriced by a margin of 10%.

READ: Sogou stock falls on weak guidance

For the second quarter, analysts expect a 14% decline in revenues to $278.37 million. However, Wall Street expects loan balance and origination volume to grow year-over-year and offset a part of the market-wide weakness that is expected to weigh on the top-line.

Second-quarter profit is projected to be 51 cents per share, compared with 32 cents per share reported last year. In the past two months, the EPS estimate has been revised from the prior projection of 43 cents per share, lending some confidence leading up to the upcoming results.

READ: JD.com reports massive earnings beat in Q2

Qudian has topped earnings estimates in all of the trailing four quarters.

The Xiamen-based firm owes its initial success to the opening up of the online credit market in China, allowing companies to set up digital platforms for small consumer credit products. However, last year the sector came under stringent regulatory scrutiny, resulting in curbs on such companies.

In the first quarter, Qudian reported stronger than expected revenues and profit, sending its shares higher.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top